{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:01Z","timestamp":1790612101480,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010029","name":"Taishan Scholars Project of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202103189"],"award-info":[{"award-number":["tsqn202103189"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MH292"],"award-info":[{"award-number":["ZR2024MH292"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IgG-mediated Nervous System Diseases Pioneer Innovative Scientific Research Public Welfare Project","award":["P119-001"],"award-info":[{"award-number":["P119-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00415-025-13258-y","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:39:06Z","timestamp":1752971946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efgartigimod for the treatment of Lambert\u2013Eaton syndrome: a case report"],"prefix":"10.1007","volume":"272","author":[{"given":"Lili","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3145-9362","authenticated-orcid":false,"given":"Yuzhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,20]]},"reference":[{"key":"13258_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/brain\/111.3.577","volume":"111","author":"JH O\u2019Neill","year":"1988","unstructured":"O\u2019Neill JH, Murray NM, Newsom-Davis J (1988) The Lambert\u2013Eaton myasthenic syndrome. A review of 50 cases. Brain 111:577\u2013596. https:\/\/doi.org\/10.1093\/brain\/111.3.577","journal-title":"Brain"},{"key":"13258_CR2","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","volume":"10","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Lang B, Verschuuren JJ (2011) Lambert\u2013Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 10:1098\u20131107. https:\/\/doi.org\/10.1016\/S1474-4422(11)70245-9","journal-title":"Lancet Neurol"},{"key":"13258_CR3","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1007\/s00415-017-8541-9","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser B, Eymard B, Datt J, Mantegazza R (2017) Lambert\u2013Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol 264:1854\u20131863. https:\/\/doi.org\/10.1007\/s00415-017-8541-9","journal-title":"J Neurol"},{"key":"13258_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/CND.0000000000000239","volume":"20","author":"P Shieh","year":"2019","unstructured":"Shieh P, Sharma K, Kohrman B, Oh SJ (2019) Amifampridine phosphate (firdapse) is effective in a confirmatory phase 3 clinical trial in LEMS. J Clin Neuromuscul Dis 20:111\u2013119. https:\/\/doi.org\/10.1097\/CND.0000000000000239","journal-title":"J Clin Neuromuscul Dis"},{"key":"13258_CR5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","volume":"82","author":"P Maddison","year":"2011","unstructured":"Maddison P, McConville J, Farrugia ME, Davies N, Rose M, Norwood F, Jungbluth H, Robb S, Hilton-Jones D (2011) The use of rituximab in myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 82:671\u2013673. https:\/\/doi.org\/10.1136\/jnnp.2009.197632","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13258_CR6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7:715\u2013725. https:\/\/doi.org\/10.1038\/nri2155","journal-title":"Nat Rev Immunol"},{"key":"13258_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ajh.25680","volume":"95","author":"AC Newland","year":"2020","unstructured":"Newland AC, S\u00e1nchez-Gonz\u00e1lez B, Rejt\u0151 L, Egyed M, Romanyuk N, Godar M et al (2020) Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol 95:178\u2013187. https:\/\/doi.org\/10.1002\/ajh.25680","journal-title":"Am J Hematol"},{"key":"13258_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/B978-0-12-823912-4.00012-8","volume":"200","author":"AF Lipka","year":"2024","unstructured":"Lipka AF, Verschuuren JJGM (2024) Lambert\u2013Eaton myasthenic syndrome. Handb Clin Neurol 200:307\u2013325. https:\/\/doi.org\/10.1016\/B978-0-12-823912-4.00012-8","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"13258_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1055\/s-0038-1660500","volume":"38","author":"H Cetin","year":"2018","unstructured":"Cetin H, Vincent A (2018) Pathogenic mechanisms and clinical correlations in autoimmune myasthenic syndromes. Semin Neurol 38(3):344\u2013354. https:\/\/doi.org\/10.1055\/s-0038-1660500","journal-title":"Semin Neurol"},{"key":"13258_CR10","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K et al (2023) Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240","journal-title":"Ther Adv Neurol Disord"},{"key":"13258_CR11","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","volume":"39","author":"ES Ward","year":"2018","unstructured":"Ward ES, Ober RJ (2018) Targeting FcRn to generate antibody-based therapeutics. Trends Pharmacol Sci 39:892\u2013904. https:\/\/doi.org\/10.1016\/j.tips.2018.07.007","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"13258_CR12","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E et al (2018) Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Investig 128(10):4372\u20134386. https:\/\/doi.org\/10.1172\/JCI97911","journal-title":"J Clin Investig"},{"key":"13258_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"issue":"6","key":"13258_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40263-024-01090-3","volume":"38","author":"N Alfaidi","year":"2024","unstructured":"Alfaidi N, Karmastaji S, Matic A, Bril V (2024) FcRn inhibitor therapies in neurologic diseases. CNS Drugs 38(6):425\u2013441. https:\/\/doi.org\/10.1007\/s40263-024-01090-3","journal-title":"CNS Drugs"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13258-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13258-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13258-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T02:38:14Z","timestamp":1756607894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13258-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["13258"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13258-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or proprietary interests in any material discussed in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This report has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Our patient provided written informed consent according to the Declaration of Helsinki. Our study obtained approval from Ethics committee of Medical Science Research, Affiliated Hospital of Jining Medical University, Jining, Shandong Province, China (Reference number, 2025\u201302-C029).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors had full access to the data in the case report and had final responsibility for the decision to submit for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"520"}}